Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial

In addition to the positive clinical results to date, Soligenix has received regulatory validation with the granting of Orphan Drug Designation and Fast Track Status by the U.S. Food and Drug Administration (FDA), and Orphan Designation by the European Medicines Agency (EMA) for HyBryte™ in the treatment of early-stage CTCL. The full article can be found at: https://prismmarketview.com/prism-marketview-highlights-soligenixs- promising-hybryte-replication-trial-setting-the-stage-for-success/ NEW YORK, June 0 ...